The single arm NOA-16 trial evaluated an IDH-specific peptide vaccination for astrocytoma with IDH1 R132H mutation in combination with radiotherapy and temozolomide for newly diagnosed patients [37]. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).